CN1284870A - 烷基氢富马酸酯在治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和局限性肠炎中的应用 - Google Patents
烷基氢富马酸酯在治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和局限性肠炎中的应用 Download PDFInfo
- Publication number
- CN1284870A CN1284870A CN98813834A CN98813834A CN1284870A CN 1284870 A CN1284870 A CN 1284870A CN 98813834 A CN98813834 A CN 98813834A CN 98813834 A CN98813834 A CN 98813834A CN 1284870 A CN1284870 A CN 1284870A
- Authority
- CN
- China
- Prior art keywords
- fumaric acid
- application
- neurodermatitis
- pharmaceutical composition
- micro tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 12
- 208000011231 Crohn disease Diseases 0.000 title claims abstract description 8
- 201000009053 Neurodermatitis Diseases 0.000 title claims abstract description 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 title claims description 7
- 239000001257 hydrogen Substances 0.000 title claims description 7
- 208000036824 Psoriatic arthropathy Diseases 0.000 title abstract 2
- -1 alkyl hydrogen Chemical compound 0.000 title abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 11
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 11
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical class COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract description 22
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002237 fumaric acid derivatives Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000053227 Themus Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- WOONQYHBMBCNDD-SYWGCQIGSA-L calcium;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Ca+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O WOONQYHBMBCNDD-SYWGCQIGSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 1
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001606075 Ganyra josephina Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HKVXSCINYRZHQK-SQQVDAMQSA-N calcium;(e)-4-methoxy-4-oxobut-2-enoic acid Chemical compound [Ca].COC(=O)\C=C\C(O)=O HKVXSCINYRZHQK-SQQVDAMQSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZHLRSUSHKGQBNV-SYWGCQIGSA-L magnesium;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O ZHLRSUSHKGQBNV-SYWGCQIGSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 229940005650 monomethyl fumarate Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DASOVGGSCVXZMC-SYWGCQIGSA-L zinc;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Zn+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O DASOVGGSCVXZMC-SYWGCQIGSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种或多种以下通式的烷基氢富马酸酯其中R是C1－5烷基,任选地与以下式的二烷基富马酸酯以及任选的常规药物学上可接受的赋形剂和载体混合,在制备微型片剂或者微型丸剂形式的、用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和局限性肠炎的药物组合物中的应用。
Description
本发明涉及游离酸形式的某些富马酸单烷基酯(烷基氢富马酸酯)在单独或者与富马酸二烷基酯组合时在制备微型片剂药物组合物中的应用，该药物组合物可用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn局限性肠炎。
给药后由于生物降解而进入柠檬酸循环或者属于该循环的药物制剂在通常高剂量时正逐渐取得更高的重要性，这是因为在它们的帮助下可以缓解或者治愈隐原性疾病。
因此，富马酸抑制鼠中Ehrlich腹水肿瘤的生长，降低丝裂霉素C和黄曲霉毒素的毒性(参考：K.Kuroda，M.Akao，Biochem.Pharmacol.29，2839-2844(1980)/Gann.72，777-782(1981)/Cancer Res.36，1900-1903(1976))，而且还具有抗牛皮癣和抗微生物作用(C.N.Huhtsnen，J.Food Sci.48，1574(1983)/M.N.Islam，US-A-4，346，118/C.A.97，161317b(1982))。
当通过非胃肠道、皮肤而且特别是经口给药时，高剂量的用于此目的的已知富马酸衍生物，如二羟基富马酸、富马酰胺和反式丁烯二腈，具有令人不可接受的副作用和高毒性(P.Holland，R.G.White，Brit.J.Dermatol.85，259-263(1971)/M.Hagedom，K.W.Kalkoff，G.Kiefer，D.Baron，J.Hug，J.Peteres，Arch.Derm.Res.254，67-73(1975))，使得该治疗通常不得不被放弃。
EP-A-0 188 749已描述了用于治疗牛皮癣的富马酸衍生物(盐)和包含该衍生物的药物组合物。
从DE-A-25 30 372中可知包含富马酸和其他富马酸衍生物之混合物的药物组合物，该组合物可用于治疗牛皮癣。富马酸的含量是强制性的。
DE-A-26 21 214描述了用于治疗牛皮癣的药物，该药物包含富马酸单乙基酯及其矿物盐作为活性成分。另外，EP-A-0 312 697描述了各种富马酸单烷基酯盐在治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn局限性肠炎中的应用。
富马酸单乙基酯盐(Ca、Zn、Mg)和富马酸二甲基酯在治疗牛皮癣中的应用从出版物“Hautarzt”(1987，279-285)中是已知的。
因为在牛皮癣性表皮中，磷脂酶A2的活性被改变，富马酸刺激该酶的事实是对本发明组合物之机理的一个可能解释。
令人惊奇的是，我们已经发现，用烷基氢富马酸酯治疗牛皮癣，即使在没有形成盐的情况下，也可用包含游离酸形式的一种或多种C1-5烷基氢富马酸酯的药物组合物来实现，该组合物还可任选地包含药物学上可接受的赋形剂和载体，而且该组合物为微型片剂或者微型丸剂。任选地，这些组合物也可包含一种或多种富马酸二烷基酯。
微型片剂或者微型丸剂的组合物使得能够给药游离酸来代替盐，并且不发生已知的副作用、特别是形成溃疡。这有可能是因为以下事实：微型片剂或者微型丸剂使药物能够均匀地分散在胃中，由此避免了游离酸形式的单烷基氢富马酸酯的局部刺激浓度。
包含20-300mg烷基氢富马酸酯的组合物特别适合于口服给药，而活性成分的总重量为100-300mg。
对于开始全身治疗或者停止该治疗，包含100-120mg活性成分的低剂量，例如30.0-35.0mg的富马酸二甲基酯和70-90mg甲基氢富马酸酯，是有利的。
190-210mg的活性成分，例如120.0mg的富马酸二甲基酯和90.0mg单乙基富马酸酯的形式，是初始阶段后的治疗剂量的一个例子。
根据本发明的组合物可以微型片剂或者经包胶的微型片剂或微型丸剂的形式经口给药，固体单个剂量药物剂型在几分钟内溶解在胃中，并由药物制剂中均匀地释放活性成分。低剂量对于开始或者停止全身给药是必须的，而初始阶段后对于治疗则需要更高的剂量。
根据本发明的微型片剂是用本领域已知的技术制造的，例如制粒、筛选、挤出/成球等。除活性成分外，它们还可包含常规的赋形剂和载体，如乳糖、PVP等。微型片剂或者微型丸剂的尺寸优选为300-2000μm，更优选为500-1500μm，并最优选为1000μm。
为便于给药单个剂量，微型片剂或者微型丸剂可进行包胶，例如包胶在明胶胶囊中。任选地，微型片剂或者微型丸剂可包覆耐胃酸的包衣。此等包衣可用已知方法包覆，例如在流化床装置中涂敷或者喷涂，或者是薄膜包衣。
实施例制造包含50.0mg甲基氢富马酸酯(相当于总共44.6mg的富马酸)并经包胶的微型丸剂
采取必要的防范措施(呼吸面罩、手套、保护衣)，用#400筛网粉碎5000kg的甲基氢富马酸酯，并均化。另外，制备2升的20％(m/v)聚乙烯吡咯烷酮(Kollidon K30)乙醇溶液。在包衣锅中引入7.250kg的Nonpareilles丸，并喷洒部分Kollidon K-30溶液直至略微湿润。然后加入部分活性成分混合物，直至丸剂干燥。继续进行该湿润/干燥步骤，直至加入所有的活性成分混合物。最后，在锅中摇动丸剂直至完全干燥。然后将丸剂填入硬明胶胶囊中(126.5mg丸剂/胶囊)。
发现对于各种临床形式的牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn局限性肠炎(Crohn病)，与包含已知成盐形式的富马酸衍生物的制剂相比，根据本发明的制剂具有类似的作用，但是没有给药游离酸时的已知副作用。急性毒性的检查
在临床实验前，通过向鼠口服给药来检查甲基氢富马酸酯的急性毒性。结果表明所用的富马酸具有非常低的毒性(见表1)。表1：鼠中的急性毒性(口服给药)
药物效力
| 性别 | 甲基氢富马酸酯 | |
| LD50 | 雄性 | 2606.8 |
| 雌性 | 1777.8 | |
| 最低致死量(mg/kg) | 雄性 | 2150.0 |
| 雌性 | 1470.0 |
分别比较Fumaderm forte(欧洲专利0 312 697 B1中的实施例4)和单甲基富马酸酯或者单乙基富马酸酯钙盐的药代动力学数据。
表2：效力
Fumaderm forte：该混合物包含120mg的富马酸二甲基酯、87mg的单乙基富马酸酯钙盐、5mg的单乙基富马酸酯镁盐、3mg的单乙基富马酸酯锌盐。
| 给药的物质 | 动物种类 | 剂量(mg/kg体重) | 甲基氢富马酸酯浓度(Cmax)/(μg/ml) |
| Fumaderm forte | 鼠 | 30 | 8.99 |
| 甲基氢富马酸酯 | 鼠 | 100 | 雄性：69.9雌性：84.5 |
| 甲基氢富马酸酯钙盐 | 鼠 | 100 | 雄性：51.3雌性：107.0 |
Claims (7)
1、一种或多种以下通式的烷基氢富马酸酯
其中R是C1-5烷基，任选地与以下式的二烷基富马酸酯以及任选的常规药物学上可接受的赋形剂和载体混合，在制备微型片剂或者微型丸剂形式的、用于治疗牛皮癣、牛皮癣性关节炎、神经性皮炎和Crohn局限性肠炎的药物组合物中的应用。
2、如权利要求1所述的应用，其特征在于使用甲基氢富马酸酯。
3、如权利要求1所述的应用，其特征在于使用甲基氢富马酸酯和富马酸二甲基酯的混合物。
4、如权利要求1-3之一所述的应用，其是用于制备微型片剂或者微型丸剂形式的口服给药的药物组合物，其特征在于活性成分的总重量为20-300mg。
5、如权利要求1-4之一所述的应用，其特征在于组合物包含10-290重量份的甲基氢富马酸酯和290-10重量份的富马酸二甲基酯。
6、如任一前述权利要求所述的应用，其是用于制备口服给药的药物组合物，其特征在于所述微型片剂或者微型丸剂具有肠溶包衣。
7、如任一前述权利要求所述的应用，其特征在于所述微型片剂或者微型丸剂的尺寸为300-2000μm。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19814358A DE19814358C2 (de) | 1998-03-31 | 1998-03-31 | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19814358.3 | 1998-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1284870A true CN1284870A (zh) | 2001-02-21 |
| CN1150898C CN1150898C (zh) | 2004-05-26 |
Family
ID=7863089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988138344A Expired - Fee Related CN1150898C (zh) | 1998-03-31 | 1998-12-08 | 富马酸单烷基酯在制备微型片剂药物组合物中的应用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6277882B1 (zh) |
| EP (1) | EP1059920B1 (zh) |
| JP (1) | JP3527890B2 (zh) |
| CN (1) | CN1150898C (zh) |
| AT (1) | ATE219936T1 (zh) |
| AU (1) | AU745281B2 (zh) |
| BG (1) | BG64744B1 (zh) |
| BR (1) | BRPI9815772B8 (zh) |
| CA (1) | CA2283915C (zh) |
| CZ (1) | CZ291788B6 (zh) |
| DE (2) | DE19814358C2 (zh) |
| DK (1) | DK1059920T3 (zh) |
| EE (1) | EE04702B1 (zh) |
| ES (1) | ES2179551T3 (zh) |
| HK (1) | HK1035134A1 (zh) |
| HU (1) | HU228848B1 (zh) |
| IL (1) | IL136835A (zh) |
| NO (1) | NO327750B1 (zh) |
| NZ (1) | NZ505341A (zh) |
| PL (1) | PL191803B1 (zh) |
| PT (1) | PT1059920E (zh) |
| RS (1) | RS49658B (zh) |
| RU (1) | RU2197233C2 (zh) |
| SK (1) | SK285187B6 (zh) |
| TR (1) | TR200001829T2 (zh) |
| WO (1) | WO1999049858A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829505B (zh) * | 2003-09-09 | 2010-11-10 | 富马法姆股份公司 | 富马酸衍生物在制备用于治疗哮喘和慢性阻塞性肺病的药物中的应用 |
| CN105496804A (zh) * | 2015-12-25 | 2016-04-20 | 知识产权全资有限公司 | 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用 |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| JP2004523511A (ja) * | 2001-01-12 | 2004-08-05 | フーマファーム アーゲー | フマル酸アミド類 |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| PT2801354T (pt) | 2004-10-08 | 2017-06-05 | Forward Pharma As | Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico |
| US20080004344A1 (en) * | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| EP1915334A2 (en) * | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| EP2186819A1 (en) | 2005-07-07 | 2010-05-19 | Aditech Pharma AG | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| JP2009510137A (ja) * | 2005-10-07 | 2009-03-12 | アディテック・ファルマ・アクチボラゲット | フマル酸エステルを含む制御放出医薬組成物 |
| EP2680007A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| UA112975C2 (uk) | 2009-01-09 | 2016-11-25 | Форвард Фарма А/С | Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти |
| CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
| RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US20130216615A1 (en) * | 2012-02-07 | 2013-08-22 | David Goldman | Pharmaceutical Compositions Containing Dimethyl Fumarate |
| WO2013119791A1 (en) | 2012-02-07 | 2013-08-15 | Xenoport, Inc. | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| KR101449114B1 (ko) * | 2012-08-21 | 2014-10-13 | 바이오스펙트럼 주식회사 | 푸마르산을 유효성분으로 포함하는 항염 조성물 |
| WO2014031844A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| EP2934503B1 (en) | 2012-12-21 | 2019-04-10 | Biogen MA Inc. | Deuterium substituted fumarate derivatives |
| SG10201707543PA (en) | 2013-03-14 | 2017-11-29 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various deseases |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| KR20210139485A (ko) | 2013-08-26 | 2021-11-22 | 에프더블유피 아이피 에이피에스 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| WO2015035184A1 (en) | 2013-09-06 | 2015-03-12 | Xenoport, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MX2017003215A (es) * | 2014-09-12 | 2018-01-24 | Tobira Therapeutics Inc | Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis. |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| ES2879611T3 (es) | 2015-02-08 | 2021-11-22 | Alkermes Pharma Ireland Ltd | Composiciones de profármaco de monometilfumarato |
| DK3273951T3 (da) | 2015-03-27 | 2020-11-02 | Symbionyx Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af psoriasis |
| WO2017060420A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2530372A1 (de) * | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) * | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| DE3127432A1 (de) * | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| DE8714143U1 (de) * | 1987-10-23 | 1988-03-24 | Werler Kunststoffwerke GmbH & Co, 4760 Werl | Sitz- und/oder Liegemöbel |
| DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
| AU1271592A (en) * | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| US5407772A (en) * | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| US5972363A (en) * | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
-
1998
- 1998-03-31 DE DE19814358A patent/DE19814358C2/de not_active Expired - Lifetime
- 1998-12-08 PT PT98965783T patent/PT1059920E/pt unknown
- 1998-12-08 RS YUP-320/00A patent/RS49658B/sr unknown
- 1998-12-08 EE EEP200000440A patent/EE04702B1/xx not_active IP Right Cessation
- 1998-12-08 IL IL13683598A patent/IL136835A/xx not_active IP Right Cessation
- 1998-12-08 CN CNB988138344A patent/CN1150898C/zh not_active Expired - Fee Related
- 1998-12-08 CZ CZ20003086A patent/CZ291788B6/cs not_active IP Right Cessation
- 1998-12-08 DK DK98965783T patent/DK1059920T3/da active
- 1998-12-08 SK SK792-2000A patent/SK285187B6/sk not_active IP Right Cessation
- 1998-12-08 CA CA002283915A patent/CA2283915C/en not_active Expired - Fee Related
- 1998-12-08 NZ NZ505341A patent/NZ505341A/en not_active IP Right Cessation
- 1998-12-08 TR TR2000/01829T patent/TR200001829T2/xx unknown
- 1998-12-08 JP JP2000540824A patent/JP3527890B2/ja not_active Expired - Fee Related
- 1998-12-08 AT AT98965783T patent/ATE219936T1/de active
- 1998-12-08 AU AU21593/99A patent/AU745281B2/en not_active Ceased
- 1998-12-08 RU RU2000127112/14A patent/RU2197233C2/ru not_active IP Right Cessation
- 1998-12-08 US US09/402,103 patent/US6277882B1/en not_active Expired - Lifetime
- 1998-12-08 DE DE59804704T patent/DE59804704D1/de not_active Expired - Lifetime
- 1998-12-08 HU HU0103234A patent/HU228848B1/hu not_active IP Right Cessation
- 1998-12-08 WO PCT/EP1998/007956 patent/WO1999049858A1/de active IP Right Grant
- 1998-12-08 BR BRPI9815772 patent/BRPI9815772B8/pt unknown
- 1998-12-08 EP EP98965783A patent/EP1059920B1/de not_active Expired - Lifetime
- 1998-12-08 ES ES98965783T patent/ES2179551T3/es not_active Expired - Lifetime
- 1998-12-08 PL PL341240A patent/PL191803B1/pl unknown
-
2000
- 2000-06-06 NO NO20002872A patent/NO327750B1/no not_active IP Right Cessation
- 2000-06-28 BG BG104566A patent/BG64744B1/bg unknown
-
2001
- 2001-08-13 HK HK01105619A patent/HK1035134A1/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829505B (zh) * | 2003-09-09 | 2010-11-10 | 富马法姆股份公司 | 富马酸衍生物在制备用于治疗哮喘和慢性阻塞性肺病的药物中的应用 |
| CN105496804A (zh) * | 2015-12-25 | 2016-04-20 | 知识产权全资有限公司 | 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150898C (zh) | 富马酸单烷基酯在制备微型片剂药物组合物中的应用 | |
| JP3881038B2 (ja) | フマル酸誘導体含有の医薬組成物 | |
| US4959389A (en) | Pharmaceutical preparation for the treatment of psoriatic arthritis | |
| CN1195511C (zh) | 富马酸衍生物在移植药物中的应用 | |
| US5424332A (en) | Pharmaceutical composition and process for the production thereof | |
| DE69731957T2 (de) | Orale pharmazeutische produkte mit peptiden | |
| CN1235578C (zh) | 富马酸微型片剂 | |
| US7612110B2 (en) | Utilization of dialkylfumarates | |
| US6458389B1 (en) | Microgranules containing cisplatin | |
| JPH09506070A (ja) | ブプロピオンを含有する安定な医薬製剤 | |
| DE3237575A1 (de) | Neue orale mopidamolformen | |
| EP0682945A2 (de) | Orale Retard-Präparation | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| DE19910682A1 (de) | Kombination von Fibraten mit einem oder mehreren Wirkstoffen, die den Homocysteinspiegel zu senken vermögen | |
| CN1038903C (zh) | 喹嗜酮化合物或其盐在制备增强生长激素释放抑制因子或抑制该因子减少的药剂中的应用 | |
| MXPA00007089A (en) | Utilization of alkyl hydrogen fumerates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis | |
| JP3521438B2 (ja) | 高脂血症予防、治療剤 | |
| IL88011A (en) | Pharmacological preparations for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and regionalitis entitis | |
| MXPA99010703A (en) | Use of fumaric acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1035134 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: BIOLOGICAL GENE EDEK INTERNATIONAL CO., LTD. Free format text: FORMER OWNER: FUMAPHARM AG Effective date: 20130613 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Swiss Swiss Patentee after: Biogene Edke International Co.,Ltd. Address before: Swiss Swiss Patentee before: Biogene Edke International Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130613 Address after: Swiss Swiss Patentee after: Biogene Edke International Co.,Ltd. Address before: Luzern, Switzerland Patentee before: Fumapharm AG |
|
| C56 | Change in the name or address of the patentee |
Owner name: BIOGEN INTERNATIONAL GMBH Free format text: FORMER NAME: BIOLOGICAL GENE EDEK INTERNATIONAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Swiss Swiss Patentee after: Bio gene International Ltd. Address before: Swiss Swiss Patentee before: Biogene Edke International Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040526 Termination date: 20161208 |